Drugs / BPI-15086
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02914990 | Dec 2016 → Mar 2019 | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-08-11 | Betta Pharmaceuticals Co., Ltd. | Results BPI-15086 I期临床研究阶段讨论会在京召开 bettapharma.com ↗
已有的临床数据提示其在T790M突变的NSCLC患者上显示出了疗效，且安全性较好。 |
| 2016-08-19 | Betta Pharmaceuticals Co., Ltd. | Regulatory 公司两项国家1.1类靶向新药X-396、BPI-15086喜获药物临床试验批件 bettapharma.com ↗
2016年7月，公司申报的两项国家1.1类靶向新药X-396、BPI-15086，喜获国家食品药品监督管理总局（CFDA）颁发的《药物临床试验批件》，批准进行I、II、III期临床试验。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-08-11 | Betta Pharmaceuticals Co., Ltd. | BPI-15086 I期临床研究阶段讨论会在京召开 bettapharma.com ↗ |
| 2016-08-19 | Betta Pharmaceuticals Co., Ltd. | 公司两项国家1.1类靶向新药X-396、BPI-15086喜获药物临床试验批件 bettapharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPI-15086 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02914990 ↗ |
| Route | Oral | “BPI-15086, orally administered daily” NCT02914990 ↗ |